|
|
|
þ
|
|
Annual
report under Section 13 or 15(d) of the Securities Exchange Act of
1934.
|
For the fiscal year ended March 31, 2007 |
o
|
|
Transition
report under Section 13 or 15(d) of the Exchange
Act.
|
Maryland
(State
or other jurisdiction of incorporation or
organization)
|
|
20-2760393
(I.R.S.
Employer Identification
No.)
|
Title
of Each Class
|
|
Name
of exchange on which registered
|
Units,
each consisting of one share of Common Stock
|
|
American
Stock Exchange
|
and
two Warrants
|
|
|
Common
Stock
|
|
American
Stock Exchange
|
Common
Stock Purchase Warrants
|
|
American
Stock Exchange
|
Page
|
||
|
PART
I
|
|
|
1
|
|
Item 1. |
10
|
|
Item 2. |
10
|
|
Item 3. |
10
|
|
Item 4. | ||
PART
II
|
||
Item 5. |
11
|
|
Item 6. |
12
|
|
Item 7. |
15
|
|
Item 8. |
15
|
|
Item 8A. |
15
|
|
Item 8B. |
16
|
|
|
|
|
PART
III
|
||
|
||
Item 9. |
17
|
|
Item 10. |
17
|
|
Item 11. |
17
|
|
Item 12. |
17
|
|
Item 13. |
18
|
|
|
||
19
|
||
Certification
|
||
Certification
|
||
Section
1350 Certification
|
||
Section
1350 Certification
|
|
•
|
|
India
is the world’s third most populous country (2006 estimate). India’s
population is approximately 1.1 billion (July 2007, estimate), with a
total labor force of approximately 509.3 million (2006
estimate).
|
|||
|
||||||
|
•
|
|
Inflation
is approximately 5.3% (2006 estimate).
|
|||
|
||||||
|
•
|
|
India’s
exports are approximately $112 billion on a free on board basis (2006
estimate).
|
|||
|
||||||
|
•
|
|
India’s
top six export partners as of 2005 are the following:
|
|||
|
1)
|
|
United
States (approximately 16.7%);
|
|||
|
||||||
|
2)
|
|
United
Arab Emirates (approximately 8.5%);
|
|||
|
||||||
|
3)
|
|
China
(approximately 6.6%);
|
|||
|
||||||
|
4)
|
|
Singapore
(approximately 5.3%); and
|
|||
|
||||||
|
5)
|
|
United
Kingdom (approximately 4.9%).
|
|
•
|
|
India’s
reserves of foreign exchange and gold are approximately $165 billion
(2006 estimate).
|
|
•
|
|
The
Indian currency is the rupee. Over the past three years on average
US
$1.00 was equivalent to
approximately:
|
|
1)
|
|
45.3
Indian rupees in 2006;
|
|
|
||||
|
2)
|
|
44.101
Indian rupees in 2005; and
|
|
|
||||
|
3)
|
|
45.317
Indian rupees in 2004.
|
|
|
|
GDP
as measured in
|
|
|
||||
|
|
terms
of PPP
|
|
Percentage
growth rate
|
||||
Nation
|
|
(2006
estimate)
|
|
(2006
estimate)
|
||||
United
States
|
|
$12.98
trillion
|
|
3.4
|
||||
China
|
|
$10.0
trillion
|
|
10.5
|
||||
Japan
|
|
$4.22
trillion
|
|
2.8
|
||||
India
|
|
$4.04
trillion
|
|
8.5
|
||||
Germany
|
|
$2.58
trillion
|
|
2.2
|
||||
United
Kingdom
|
|
$1.903
trillion
|
|
2.7
|
||||
France
|
|
$1.871
trillion
|
|
2.0
|
||||
Italy
|
|
$1.727
trillion
|
|
1.6
|
|
•
|
|
Knowledge-based
and Other Back Office Outsourcing: As labor costs for information
technology and similar professionals soar in the U.S. and technology
facilitates communication between persons in disparate parts of the
world,
we believe that the benefits of outsourcing knowledge-based and back
office functions to countries such as India will be increasingly
utilized
by businesses all over the world. We may consider sectors, such as
software development, research and development, information technology,
telecommunications outsourcing, financial services, and customer
care.
|
|
•
|
|
Pharmaceutical
and Health Services: As healthcare costs soar in the U.S., we believe
that
the benefits of outsourcing medical services, drug manufacturing
or
medical transcription to countries such as India, will be increasingly
utilized in the healthcare industry and by consumers all over the
world.
For example, medical transcription (where medical dictation is converted
by workers in India into print) is an area that has taken advantage
of the
lower labor rates in India and other countries. Other areas that
are
expected to benefit from outsourcing are generic drug manufacturing,
drug
trial testing, and telemedicine. For example, we may consider buying
a
middle-tier generic drug manufacturer with a U.S. Federal Drug
Administration approved manufacturing plant and combining it with
a
distributor in the U.S. to create a vertical generic drug manufacturing
and distribution company.
|
|
•
|
|
financial
condition, results of operation and repatriation
regulations;
|
|
|||
|
•
|
|
growth
potential both in India and growth potential outside of
India;
|
|
|||
|
•
|
|
capital
requirements;
|
|
|||
|
•
|
|
experience
and skill of management and availability of additional
personnel;
|
|
|||
|
•
|
|
competitive
position;
|
|
|||
|
•
|
|
barriers
to entry into the businesses’ industries;
|
|
|||
|
•
|
|
potential
for compliance with generally accepted accounting principles (GAAP),
SEC
regulations, Sarbanes-Oxley requirements and capital
requirements;
|
|
|||
|
•
|
|
domestic
and global competitive position and potential to compete in the U.S.
and
other markets;
|
|
|||
|
•
|
|
position
within a sector and barriers to entry;
|
|
|||
|
•
|
|
stage
of development of the products, processes or services;
|
|
|||
|
•
|
|
degree
of current or potential market acceptance of the products, processes
or
services;
|
|
|||
|
•
|
|
proprietary
features and degree of intellectual property or other protection
of the
products, processes or services;
|
|
|||
|
•
|
|
regulatory
environment of the industry and the Indian government’s policy towards the
sector; and
|
|
|||
|
•
|
|
costs
associated with effecting the business
combination.
|
Item 2.
|
Description
of Property
|
Legal
Proceedings
|
Submission
of Matters to a Vote of Security
Holders
|
Fiscal
Year Ended March 31, 2007
|
High
|
|
Low
|
|||
First
Quarter
|
|
$
|
6.50
|
|
$
|
6.35
|
Second
Quarter
|
6.60
|
6.00
|
||||
Third
Quarter
|
7.74
|
6.22
|
||||
Fourth
Quarter
|
7.70
|
|
|
6.85
|
||
|
|
|
||||
Fiscal
Year Ended March 31, 2006
|
|
|||||
March 31,
2006
|
|
$
|
6.75
|
|
$
|
6.31
|
|
|
Aggregate
price of the
|
|
|
|
|
|
Aggregate
price of the
|
||||
Amount
Registered
|
|
amount
registered
|
|
Amount
Sold
|
|
amount
sold to date
|
||||||
11,304,500
units
|
|
$
|
67,827,000
|
|
|
11,304,500
units
|
|
$
|
67,827,000
|
|
|
•
|
May
significantly reduce the equity interest of our
stockholders;
|
|
||
|
•
|
will
likely cause a change in control if a substantial number of our shares
of
common stock or voting preferred stock are issued, which may affect,
among
other things, our ability to use our net operating loss carry forwards,
if
any, and may also result in the resignation or removal of one or
more of
our present officers and directors;
|
|
||
|
•
|
may
adversely affect the voting power or other rights of holders of our
common
stock if we issue preferred stock with dividend, liquidation, conversion
or other rights superior to the common stock; and
|
|
||
|
•
|
May
adversely affect prevailing market prices for our common stock, warrants
or units.
|
|
•
|
may
lead to default and foreclosure on our assets if our operating revenues
after a business combination are insufficient to pay our debt
obligations;
|
|
|
•
|
may
cause an acceleration of our obligations to repay the debt even if
we make
all principal and interest payments when due if we breach the covenants
contained in the terms of the debt documents, such as covenants that
require the maintenance of certain financial ratios or reserves,
without a
waiver or renegotiation of such covenants;
|
|
|
|||
|
•
|
may
create an obligation to immediately repay all principal and accrued
interest, if any, upon demand to the extent any debt securities are
payable on demand; and
|
|
|
|||
|
•
|
may
hinder our ability to obtain additional financing, if necessary,
to the
extent any debt securities contain covenants restricting our ability
to
obtain additional financing while such security is outstanding, or
to the
extent our existing leverage discourages other potential
investors.
|
|
•
|
Payment
of the purchase price for the business combination;
|
|
||
|
•
|
Payment
of the fees and costs due to Ferris, Baker Watts, Inc. as representative
of the underwriters and financial advisor to the
company;
|
|
||
|
•
|
Payment
of any finder’s fees or professional fees and costs;
and
|
|
||
|
•
|
Payment
of any fees and costs the Company may incur in connection with any
equity
or debt financing relating to the business combination.
|
|
||
|
•
|
In
addition, the Company will repay the outstanding balance of the aggregate
$870,000 in loans made by Mr. Mukunda and Dr. Krishna to the
Company and any deferred expenses.
|
|
•
|
Approximately
$300,000 of expenses for legal, accounting and other expenses attendant
to
the due diligence investigations, structuring and negotiating of
a
business combination; as of March 31, 2007 we have incurred approximately
$330,000 of expenses.
|
|
|
|||
|
•
|
Approximately
$185,000 of expenses for the due diligence and investigation of a
target
business; as of March 31, 2007 we have incurred approximately $153,000
of
expenses.
|
|
|
|||
|
•
|
Approximately
$115,000 of expenses in legal and accounting fees relating to our
SEC
reporting obligations; as of March 31, 2007 we have incurred approximately
$200,000 of expenses.
|
|
|
•
|
As
of March 30, 2007, there were approximately 67,000 unit holders of
record,
600 stockholders and 600 holders of warrants. The last sale price as
reported by the American Stock Exchange on March 30, 2007, was $6.85
for
units, $ 5.84 for shares and $ 0.69 for warrants. The Company has
never
paid a cash dividend on its common stock and does not anticipate
the
payment of cash dividends in the foreseeable future.
|
|
|
|||
|
•
|
Approximately
$184,000 for travel, general working capital that will be used for
miscellaneous expenses and reserves, including for director and officer
liability insurance premiums, deposits, down payments and/or funding
of a
“no shop” provision in connection with a prospective business transaction
and for international travel with respect to negotiating and finalizing
a
business combination. As of March 31, 2007 we have incurred approximately
$150,000 for travel and general working capital. We have made a $3,000,000
payment to MBL to serve as a “no shop” fee. Subsequent to March
31, 2007, we have also made approximately a $250,000 payment to CWEL
as a
no shop fee.
|
|
•
|
our
obligation to seek stockholder approval of a business combination
or
obtain the necessary financial statements to be included in the proxy
materials to be sent to stockholders in connection with a proposed
business combination may delay the completion of a
transaction;
|
|
|
|||
|
•
|
our
obligation to convert into cash shares of common stock held by our
public
stockholders in certain instances may reduce the resources available
to us
for a business combination; and
|
|
|
|||
|
•
|
our
outstanding warrants and the purchase option granted to Ferris, Baker
Watts, Inc., and the future dilution they potentially represent,
may not
be viewed favorably by certain target businesses.
|
|
Exhibit
No.
|
Exhibit
|
|
3.1
|
Amended
and Restated Articles of Incorporation.(1)
|
|
3.2
|
|
By-laws.(2)
|
4.1
|
Specimen
Unit Certificate.(3)
|
|
4.2
|
Specimen
Common Stock Certificate.(3)
|
|
4.3
|
Specimen
Warrant Certificate.(3)
|
|
4.4
|
Form
of Warrant Agreement between Continental Stock Transfer & Trust
Company and the Registrant.(1)
|
|
4.5
|
Form
of Purchase Option to be granted to the
Representative.(1)
|
|
10.1
|
Amended
and Restated Letter Agreement between the Registrant, Ferris, Baker
Watts,
Inc. and Ram Mukunda.(4)
|
|
10.2
|
Amended
and Restated Letter Agreement between the Registrant, Ferris, Baker
Watts,
Inc. and John Cherin.(4)
|
|
10.3
|
Amended
and Restated Letter Agreement between the Registrant, Ferris, Baker
Watts,
Inc. and Ranga Krishna.(4)
|
|
10.4
|
Form
of Investment Management Trust Agreement between Continental Stock
Transfer & Trust Company and the Registrant.(5)
|
|
10.5
|
Promissory
Note issued by the Registrant to Ram Mukunda.(2)
|
|
10.5.1
|
Extension
of Due Date of Promissory Note issued to Ram
Mukunda.(2)
|
|
10.6
|
Form
of Stock and Unit Escrow Agreement among the Registrant, Ram Mukunda,
John
Cherin and Continental Stock Transfer & Trust
Company.(2)
|
|
10.7
|
Form
of Registration Rights Agreement among the Registrant and each of
the
existing stockholders.(3)
|
|
10.8
|
Form
of Unit Purchase Agreement among Ferris, Baker Watts, Inc. and one
or more
of the Initial Stockholders.(5)
|
|
10.9
|
Form
of Office Service Agreement between the Registrant and Integrated
Global
Networks, LLC.(5)
|
|
10.10
|
Amended
and Restated Letter Advisory Agreement between the Registrant, Ferris,
Baker Watts, Inc. and SG Americas Securities, LLC.(5)
|
|
10.11
|
Form
of Letter Agreement between Ferris, Baker Watts, Inc. and certain
officers
and directors of the Registrant.(4)
|
|
10.12
|
Form
of Letter Agreement between Ferris, Baker Watts, Inc. and each of
the
Special Advisors of the Registrant.(4)
|
|
10.13
|
Form
of Letter Agreement between the Registrant and certain officers and
directors of the Registrant.(4)
|
|
10.14
|
Form
of Letter Agreement between the Registrant and each of the Special
Advisors of the Registrant.(4)
|
|
10.15
|
Promissory
Note issued by the Registrant to Ranga Krishna.(2)
|
|
10.15.1
|
Extension
of Due Date of Promissory Note issued to Ranga
Krishna.(2)
|
|
10.16
|
Form
of Promissory Note to be issued by the Registrant to Ranga
Krishna.(2)
|
|
10.17
|
Share
Subscription Cum Purchase Agreement dated February 2, 2007 by and
among India Globalization Capital, Inc., MBL Infrastructures Limited
and
the persons “named as Promoters therein”.(6)
|
|
10.18
|
Debenture
Subscription Agreement dated February 2, 2007 by and among India
Globalization Capital, Inc., MBL Infrastructures Limited and the
persons
named as Promoters therein. (6)
|
|
10.19
|
Note
and Warrant Purchase Agreement dated February 5, 2007 by and among
India Globalization Capital, Inc. and Oliviera Capital,
LLC.(6)
|
|
10.20
|
Promissory
Note dated February 5, 2007 in the initial principal amount for
$3,000,000 issued by India Globalization Capital, Inc. to Oliviera
Capital, LLC.(6)
|
|
10.21
|
Warrant
to Purchase Shares of Common Stock of India Globalization Capital,
Inc.
issued by India Globalization Capital, Inc. to Oliviera Capital,
LLC.(6)
|
|
10.22
|
|
First
Amendment to Share Subscription Cum Purchase Agreement dated February
2,
2007 by and among India Globalization Capital, Inc., MBL Infrastructures
Limited and the persons named as Promoters therein.(7)
|
10.23
|
First
Amendment to the Debenture Subscription Agreement dated February
2, 2007
by and among India Globalization Capital, Inc., MBL Infrastructures
Limited and the persons named as Promoters therein.(7)
|
|
10.24
|
Contract
Agreement dated April 29, 2007 between IGC, CWEL, AMTL and
MAIL.(7)
|
|
31.1
|
Certificate
pursuant to 17 CFR 240.13a-14(a).
|
|
31.2
|
Certificate
pursuant to 17 CFR 240.13a-14(a).
|
|
32.1
|
Certificate
pursuant to 18 U.S.C. § 1350.
|
|
32.2
|
Certificate
pursuant to 18 U.S.C. § 1350.
|
(1)
|
Incorporated
by reference to the Registrant’s Registration Statement on Form S-1 (SEC
File No. 333-124942), as amended and filed on September 22,
2006.
|
(2)
|
Incorporated
by reference to the Registrant’s Registration Statement on Form S-1 (SEC
File No. 333-124942), as amended and filed on February 14,
2006.
|
(3)
|
Incorporated
by reference to the Registrant’s Registration Statement on Form S-1 (SEC
File No. 333-124942), as originally filed on May 13,
2005.
|
(4)
|
Incorporated
by reference to the Registrant’s Registration Statement on Form S-1 (SEC
File No. 333-124942), as amended and filed on July 11,
2005.
|
(5)
|
Incorporated
by reference to the Registrant’s Registration Statement on Form S-1 (SEC
File No. 333-124942), as amended and filed on March 2,
2006.
|
(6)
|
Incorporated
by reference to the Registrant’s Current Report on Form 8-K (SEC File No.
333-124942), as originally filed on February 12,
2007.
|
(7)
|
Incorporated
by reference to the Registrant’s Current Report on Form 8-K (SEC File No.
333-124942), as originally filed on May 2,
2007.
|
|
|
|
|
Page
|
|
F-1
|
||
F-2
|
||
F-3
|
||
F-4
|
||
F-5
|
||
F-6
|
March
31,
|
||||||||
2007
|
2006
|
|||||||
ASSETS
|
||||||||
Current
Assets:
|
||||||||
Cash
and cash equivalents
|
$ |
1,169,422
|
$ |
2,210
|
||||
Investments
held in Trust Fund
|
66,104,275
|
65,825,016
|
||||||
Interest Receivable—Convertible Debenture | 37,479 | - | ||||||
Convertible
debenture in MBL
|
3,000,000
|
-
|
||||||
Prepaid
expenses and other current assets
|
74,197
|
76,766
|
||||||
Total
Current Assets
|
70,385,373
|
65,903,992
|
||||||
Deferred
acquisition costs
|
158,739
|
- | ||||||
Deferred
tax assets—Federal and State, net of valuation allowance
|
142,652
|
25,000
|
||||||
Total
Assets
|
$ |
70,686,764
|
$ |
65,928,992
|
||||
LIABILITIES
AND STOCKHOLDERS’ EQUITY
|
||||||||
Current
Liabilities:
|
||||||||
Accrued
expenses
|
$ |
237,286
|
$ |
286,105
|
||||
Notes
payable to stockholders
|
870,000
|
870,000
|
||||||
Taxes
payable
|
296,842
|
70,000
|
||||||
Deferred
trust interest
|
32,526
|
-
|
||||||
Note
Payable to Oliveira Capital, LLC
|
1,794,226
|
-
|
||||||
Due
to underwriter
|
1,769,400
|
1,769,400
|
||||||
Total
current liabilities
|
$ |
5,000,280
|
$ |
2,995,505
|
||||
Common
stock subject to possible conversion, 2,259,770 at conversion value
(Note
A)
|
12,762,785
|
12,762,785
|
||||||
COMMITMENTS
AND CONTINGENCY
|
||||||||
STOCKHOLDERS’
EQUITY
|
||||||||
Preferred
stock $.0001 par value; 1,000,000 shares authorized; none issued
and
outstanding
|
—
|
—
|
||||||
Common
stock — $.0001 par value; 75,000,000 shares authorized; issued and
outstanding 13,974,500
|
1,397
|
1,397
|
||||||
Additional
paid-in capital
|
51,848,145
|
50,613,145
|
||||||
Income
(Deficit) accumulated during the development stage
|
1,074,157
|
(443,840 | ) | |||||
Total
stockholders’ equity
|
$ |
52,923,699
|
$ |
50,170,702
|
||||
TOTAL
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$ |
70,686,764
|
$ |
65,928,992
|
|
|
|
April
29, 2005
|
|
April
29, 2005
|
|
||||
|
|
|
(Date
of Inception)
|
|
(Date
of Inception)
|
|
||||
|
Year
Ended
|
|
|
through
|
|
Through
|
|
|||
|
March
31, 2007
|
|
|
March
31, 2006
|
|
March
31, 2007
|
|
|||
Legal
and formation, travel and other start up costs
|
$
|
(765,047
|
)
|
|
$
|
(68,183
|
)
|
$
|
(833,230
|
)
|
Compensation
expense
|
|
—
|
|
|
|
(535,741
|
)
|
|
(535,741
|
)
|
Interest
expense
|
|
(103,916
|
)
|
|
|
(5,500
|
)
|
|
(106,416
|
)
|
Interest
income
|
|
3,171,818
|
|
|
|
210,584
|
|
|
3,382,402
|
|
|
|
|
|
|
|
|
|
|||
Income
(loss) before income taxes
|
|
2,302,855
|
|
|
|
(398,840
|
)
|
|
1,904,015
|
|
Provision
for income taxes, net
|
|
784,858
|
|
|
|
45,000
|
|
|
829,858
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss)
|
$
|
1,517,997
|
|
|
$
|
(443,840
|
)
|
$
|
1,074,157
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss) per share: basic and diluted
|
$
|
0.11
|
|
|
$
|
(0.14
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Weighted
average number of shares
|
|
|
|
|
|
|
|
|
|
|
outstanding-basic
and diluted
|
|
13,974,500
|
|
|
|
3,191,000
|
|
|
|
|
Common
Stock
|
||||||||||||||
Shares
|
Amount
|
Additional
Paid-in Capital |
Income
(Deficit) Accumulated
During
the Development Stage
|
Total
Stockholders’
Equity
|
||||||||||
Issuance
of common stock to founders at $.01 per share (1,750,000 shares on
May 5, 2005 and 750,000 shares on June 20, 2005)
|
2,500,000
|
$ |
250
|
$ |
24,750
|
—
|
$ |
25,000
|
||||||
|
||||||||||||||
Surrendered
shares (on September 7, 2005 and February 5, 2006 of 62,500 and
137,500 respectively)
|
(200,000 | ) | (20 | ) |
20
|
—
|
—
|
|||||||
|
||||||||||||||
Issuance
of common stock to founders at $.01 per share on February 5,
2006
|
200,000
|
20
|
537,721
|
—
|
537,741
|
|||||||||
|
||||||||||||||
Issue
of 170,000 units in a private placement
|
170,000
|
17
|
1,019,983
|
—
|
1,020,000
|
|||||||||
|
||||||||||||||
Issue
of 11,304,500 units, net of underwriters’ discount and offering expenses
(including 2,259,770 shares subject to possible conversion) and $100
from
underwriters option
|
11,304,500
|
1,130
|
61,793,456
|
—
|
61,794,586
|
|||||||||
|
||||||||||||||
Proceeds
subject to possible conversion of shares
|
(12,762,785 | ) |
—
|
(12,762,785
|
) | |||||||||
|
||||||||||||||
Net
loss for the period
|
—
|
—
|
—
|
$ | (443,840 | ) |
(443,840
|
) | ||||||
|
||||||||||||||
Balance
at March 31, 2006
|
13,974,500
|
$ |
1,397
|
$ |
50,613,145
|
$ | (443,840 | ) | $ |
50,170,702
|
||||
|
||||||||||||||
Fair
value of 425,000 warrants issued to Oliveira Capital, LLC
|
—
|
—
|
1,235,000
|
—
|
1,235,000
|
|||||||||
Net
income
|
—
|
—
|
—
|
$ |
1,517,997
|
1,517,997
|
||||||||
Balance
at March 31, 2007
|
13,974,500
|
$ |
1,397
|
$ |
51,848,145
|
$ |
1,074,157
|
$ |
52,923,699
|
Year ended
March 31, 2007 |
April
29, 2005
(Date of Inception)Through March 31, 2006 |
April
29, 2005
(Date
of Inception)
Through
March
31, 2007
|
|||||||
Cash flows from operating activities: | |||||||||
Net income (loss) | $ |
1,517,997
|
$ | (443,840 | ) | $ |
1,074,157
|
||
Adjustment to reconcile net income (loss) to net cash used in operating activities: | |||||||||
Interest earned on Treasury Bills | (3,098,769 | ) | (203,022 | ) | (3,301,791 | ) | |||
Non-cash compensation expense | - |
535,741
|
535,741
|
||||||
Deferred taxes | (117,652 | ) | (25,000 | ) | (142,652 | ) | |||
Amortization of debt discount on Oliveira debt |
29,226
|
- |
29,226
|
||||||
Changes in: | |||||||||
Prepaid
expenses and other current assets
|
2,569
|
(76,766 | ) | (74,197 | ) | ||||
Interest
receivable - convertible debenture
|
(37,479 | ) | - | (37,479 | ) | ||||
Deferred
interest liability
|
32,526
|
- |
32,526
|
||||||
Accrued
expenses
|
(113,819 | ) |
47,679
|
(66,140 | ) | ||||
Taxes
payable
|
226,842
|
70,000
|
296,842
|
||||||
Net cash used in operating activities | (1,558,559 | ) | (95,208 | ) | (1,653,767 | ) | |||
Cash flows from investing activities: | |||||||||
Purchase of treasury bills | (722,540,587 | ) | (131,229,427 | ) | (853,770,014 | ) | |||
Maturity of treasury bills |
725,189,331
|
65,780,000
|
790,969,331
|
||||||
Decrease (increase) in cash held in trust |
170,766
|
(172,567 | ) | (1,801 | ) | ||||
Purchase of convertible debenture | (3,000,000 | ) | - | (3,000,000 | ) | ||||
Payment of deferred acquisition costs | (93,739 | ) | - | (93,739 | ) | ||||
Net cash used in investing activities | (274,229 | ) | (65,621,994 | ) | (65,896,223 | ) | |||
Cash flows from financing activities: | |||||||||
Issuance of common stock to founders |
27,000
|
27,000
|
|||||||
Payments of offering costs | (4,024,688 | ) | (4,024,688 | ) | |||||
Proceeds from notes payable to stockholders |
870,000
|
870,000
|
|||||||
Proceeds from issuance of underwriters option |
100
|
100
|
|||||||
Proceeds from initial public offering |
67,827,000
|
67,827,000
|
|||||||
Proceeds
from private placement
|
1,020,000
|
1,020,000
|
|||||||
Proceeds
from note payable to Oliveira Capital, LLC
|
3,000,000
|
- |
3,000,000
|
||||||
Net
cash provided by financing activities
|
3,000,000
|
65,719,412
|
68,719,412
|
||||||
Net
increase in cash and cash equivalent
|
1,167,212
|
2,210
|
1,169,422
|
||||||
Cash
and cash equivalent at the beginning of the
period
|
2,210
|
- | - | ||||||
Cash
and cash equivalent at the end of the period
|
$ |
1,169,422
|
$ |
2,210
|
$ |
1,169,422
|
|||
Supplemental
schedule of non cash financing activities:
|
|||||||||
Accrual of offering costs | $ |
-
|
$ |
238,426
|
$ |
238,426
|
|||
Accrual
of deferred underwriters’ fees
|
$ |
-
|
$ |
1,769,400
|
$ |
1,769,400
|
|||
Accrual
of deferred acquisition costs
|
$ |
65,000
|
$ | - | $ | 65,000 | |||
Supplemental
disclosure of cash flow information:
|
|||||||||
Interest
paid
|
$ |
-
|
$ | - | $ | - | |||
Income taxes paid | $ |
675,668
|
$ | - | $ |
675,668
|
|||
Fair
value of warrants included in additional paid in
capital
|
$ |
1,235,000
|
$ | - | $ |
1,235,000
|
|
March
31,
|
||||||
|
2007
|
2006
|
|||||
Investment
held for the benefit of the Company
|
$ |
63,845,850
|
$ |
63,845,850
|
|||
Investment
held for the benefit of the Underwriter
|
1,769,400
|
1,769,400
|
|||||
Investment
earnings (available to fund Company expenses up to a maximum of
$2,150,000, net of taxes)(1)
|
489,025
|
209,766
|
|||||
|
|
|
|||||
|
$ |
66,104,275
|
$ |
65,825,016
|
|||
(1)
Through March 31, 2007, the Company has transferred approximately
$2,150,000 of Investment Earnings from the Trust Account into its
operating account.
|
|
|
|
March
31,
|
||||||
2007
|
2006
|
||||||
Current:
|
|
||||||
Federal
|
$ |
902,510
|
$ |
70,000
|
|||
Deferred:
|
|||||||
Federal
|
(117,652
|
) | (25,000 | ) | |||
|
|||||||
Total
tax provision
|
$ |
784,858
|
$ |
45,000
|
|
March
31,
|
||||||
2007
|
2006
|
||||||
Statutory
Federal income tax rate
|
34 | % | 34 | % | |||
Non-cash compensation expense | (45.7 | )% | |||||
State
tax benefit net of federal tax
|
(1.3 | )% | (1.3 | )% | |||
Increase
in state valuation allowance
|
1.3 | % | 1.3 | % | |||
Other
|
-
|
.4 | % | ||||
|
|||||||
Effective
income tax rate
|
34 | % | (11.3 | )% |
March
31,
|
|||||||
2007
|
2006
|
||||||
Operating costs deferred for income tax purposes | $ |
242,015
|
$ |
30,000
|
|||
Interest
income deferred for reporting purposes
|
11,059
|
- | |||||
Difference between accrual accounting for reporting purposes and cash accounting for tax purposes | (75,514 | ) | - | ||||
Less: Valuation Allowance | (34,908 | ) | (5,000 | ) | |||
Net deferred tax asset | $ |
142,652
|
$ |
25,000
|
INDIA GLOBALIZATION CAPITAL, INC. | |||
Date:
July 16, 2007
|
By:
|
/s/ Ram Mukunda | |
Ram Mukunda | |||
Chief Executive Officer and President (Principal Executive Officer) | |||
Date:
July 16, 2007
|
By:
|
/s/ John B. Selvaraj | |
John B. Selvaraj | |||
Treasurer, Principal Financial and Accounting Officer | |||
Date:
July 16, 2007
|
By:
|
/s/ Dr. Ranga Krishna | |
Dr. Ranga Krishna | |||
Director | |||
Date:
July 16, 2007
|
By:
|
/s/ Sudhakar Shenoy | |
Sudhakar Shenoy | |||
Director | |||
Date:
July 16, 2007
|
By:
|
/s/ Ram Mukunda, | |
Ram Mukunda | |||
Director | |||
Date:
July 16, 2007
|
By:
|
/s/ Richard Prince | |
Richard Prince | |||
Director | |||